Raymond James Financial Reaffirms Buy Rating for Heska (HSKA)

Raymond James Financial reissued their buy rating on shares of Heska (NASDAQ:HSKA) in a report issued on Monday, December 4th.

A number of other research analysts also recently commented on the stock. B. Riley reiterated a hold rating and set a $96.50 price objective on shares of Heska in a research note on Friday, October 27th. Canaccord Genuity initiated coverage on shares of Heska in a research report on Thursday, October 5th. They issued a buy rating and a $115.00 price target on the stock. BidaskClub downgraded shares of Heska from a buy rating to a hold rating in a research report on Monday, August 14th. Zacks Investment Research cut shares of Heska from a buy rating to a hold rating in a report on Wednesday, October 4th. Finally, Benchmark reaffirmed a buy rating and issued a $120.00 price objective (up previously from $106.00) on shares of Heska in a report on Wednesday, August 9th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Heska currently has a consensus rating of Buy and a consensus price target of $113.30.

Heska (NASDAQ:HSKA) traded down $1.02 during trading hours on Monday, hitting $80.21. 62,822 shares of the stock were exchanged, compared to its average volume of 90,711. The firm has a market capitalization of $588.41, a price-to-earnings ratio of 42.53, a PEG ratio of 2.16 and a beta of 0.75. Heska has a twelve month low of $70.49 and a twelve month high of $115.00.

Heska (NASDAQ:HSKA) last released its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.03. Heska had a net margin of 10.67% and a return on equity of 15.35%. The company had revenue of $31.40 million during the quarter, compared to analyst estimates of $36.10 million. During the same quarter in the prior year, the business earned $0.45 earnings per share. The business’s quarterly revenue was down 6.0% compared to the same quarter last year. sell-side analysts forecast that Heska will post 2.03 earnings per share for the current year.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total transaction of $681,957.64. Following the transaction, the insider now owns 106,771 shares of the company’s stock, valued at approximately $9,304,024.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 14.70% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of HSKA. Royal Bank of Canada boosted its holdings in shares of Heska by 96.9% in the second quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after buying an additional 499 shares during the period. SG Americas Securities LLC acquired a new position in shares of Heska in the third quarter worth about $108,000. Victory Capital Management Inc. boosted its holdings in shares of Heska by 17.5% during the second quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock worth $116,000 after purchasing an additional 169 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of Heska during the second quarter worth approximately $127,000. Finally, LS Investment Advisors LLC boosted its holdings in shares of Heska by 411.2% during the second quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock worth $130,000 after purchasing an additional 1,028 shares during the period. Institutional investors own 80.89% of the company’s stock.

WARNING: “Raymond James Financial Reaffirms Buy Rating for Heska (HSKA)” was first reported by Week Herald and is the property of of Week Herald. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://weekherald.com/2017/12/30/heska-hska-earns-buy-rating-from-raymond-james-financial.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply